PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Advanced viral gene therapy eradicates prostate cancer in preclinical experiments

Novel therapy shows synergism between engineered 'cancer terminator virus' and experimental drug to destroy primary and metastatic prostate cancer

Advanced viral gene therapy eradicates prostate cancer in preclinical experiments
2015-05-11
(Press-News.org) Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.

Recently published in the journal Oncotarget, this new study is the most recent in a long line of studies led by Paul B. Fisher, M.Ph., Ph.D., investigating the use of viral gene therapy to treat a variety of cancers. The treatment strategy uses a novel "cancer terminator virus" (CTV), which replicates exclusively in cancer cells delivering the cancer-specific, toxic cytokine gene mda-7/IL-24 directly to the tumor. The researchers added an experimental drug known as BI-97D6, which targets MCL-1 and other members of the Bcl-2 gene family that protect cancer cells from therapeutic agents, resulting in enhanced prostate cancer cell death while sparing healthy prostate epithelial cells in preclinical experiments involving advanced mouse models of prostate cancer. The therapy not only killed cells at the primary tumor site, but also in distant metastases by "bystander" antitumor activity driven by the secreted MDA-7/IL-24 protein.

"We are at a point in our research where we have validated the efficacy of this combination treatment approach in preclinical animal models, and we now need to define its safety through toxicology and pharmacology studies," says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine. "We are hopeful that this research will culminate in the development of a phase 1 clinical trial that will test the safety of this novel approach and potentially lead to an effective new therapy for advanced prostate cancer."

When viruses attack their hosts, they introduce their genetic material into the host cell. This process essentially hijacks the cell in order to produce more copies of the virus. The CTV used in the study, Ad.tCCN1-CTV-m7, is a modified adenovirus--the kind of virus that typically causes mild respiratory infections. The scientists removed the genes controlling viral replication and that cause disease, and they added part of the controlling element of a gene known as CCN1 to cause the virus to replicate selectively in cancer cells. The scientists then engineered the virus to deliver the tumor-suppressing and -cell-death inducing gene mda-7/IL-24 into the cancer cells, generating a CTV. As the CTV continues to replicate, it causes the cells to produce and secrete mda-7/IL-24.

The mda-7/IL-24 gene was originally discovered by Fisher, who showed in previous studies that it prevents tumor growth and inhibits tumor blood vessel formation, promotes anti-tumor immune effects and stimulates a form of cell suicide known as apoptosis. The gene has also been shown to synergize with other cancer treatments. In the present study, the scientists demonstrated that the drug BI-97D6 increased cancer cell death caused by mda-7/IL-24, and it also helped defend against resistance to the viral gene therapy.

Critical to the therapy is the stealth delivery technique known as ultrasound-targeted microbubble destruction (UTMD). If injected directly into the bloodstream by itself, the CTV may get trapped in the liver or be removed by the body's immune system. UTMD uses microscopic, gas-filled bubbles that can be paired with viral therapies, therapeutic genes and proteins, and imaging agents. The bubbles are released in a site-and target-specific manner via ultrasound, and, with appropriate modification of the therapeutic virus, can be imaged in real-time to track the delivery of the CTV to the tumor. Fisher and his colleagues are pioneering this approach and have already reported success in preclinical experiments utilizing UTMD technology and mda-7/IL-24 gene therapy in prostate and colorectal cancer models. UTMD has also been used elsewhere in clinical trials testing therapies for patients with heart disease.

"This approach holds promise for the treatment of many different cancers ," says Fisher. "Our team is collaborating with researchers at Massey and at other institutions to move this research forward. We even plan to open a phase 1 clinical trial next year testing a different CTV expressing mda-7/IL-24 in patients with recurrent brain cancer."

INFORMATION:

Fisher collaborated on this research with Devanand Sarkar, M.B.B.S., Ph.D., Harrison Scholar and member of the Cancer Molecular Genetics research program at Massey, Blick Scholar and associate professor in the Department of Human and Molecular Genetics at the VCU School of Medicine and associate scientific director of cancer therapeutics in the VIMM; Swadesh K. Das, Ph.D., member of the Massey Cancer Molecular Genetics research program, VIMM member and assistant professor in the VCU Department of Human and Molecular Genetics; Xiang-Yang Wang, Ph.D., Harrison Scholar and member of the Massey Cancer Molecular Genetics program, associate scientific director of immunology and infectious diseases in the VIMM and professor in the VCU Department of Human and Molecular Genetics; Luni Emdad, M.B.B.S., Ph.D., member of the Massey Cancer Molecular Genetics research program, VIMM member and assistant professor in the VCU Department of Human and Molecular Genetics; Siddik Sarkar, Ph.D., postdoctoral research scientist in the VCU Department of Human and Molecular Genetics; Bridget A. Quinn, Ph.D., M.D./Ph.D. student in the VCU Department of Human and Molecular Genetics; Xue-Ning Shen, M.D., senior research technician in the VCU Department of Human and Molecular Genetics; and Rupesh Dash, Ph.D., former postdoctoral research scientist in the VCU Department of Human and Molecular Genetics; Alexander L. Klibanov, Ph.D., associate professor at the University of Virginia; and Maurizio Pellecchia, professor at Sanford-Burnham Medical Research Institute.

This study was supported by National Institutes of Health/National Cancer Institute grant R01 CA168517, Department of Defense grants W81XWH-11-1-0186 and W81XWH-11-1-0480, the Natioanl Foundation for Cancer Research, and, in part, by VCU Massey Cancer Center's NIH-NCI Cancer Center Support Grant P30 CA016059.


[Attachments] See images for this press release:
Advanced viral gene therapy eradicates prostate cancer in preclinical experiments

ELSE PRESS RELEASES FROM THIS DATE:

New method developed to assess cancer risk of pollutants

New method developed to assess cancer risk of pollutants
2015-05-11
CORVALLIS, Ore. - Scientists at Oregon State University have developed a faster, more accurate method to assess cancer risk from certain common environmental pollutants. Researchers found that they could analyze the immediate genetic responses of the skin cells of exposed mice and apply statistical approaches to determine whether or not those cells would eventually become cancerous. The study focused on an important class of pollutants known as polycyclic aromatic hydrocarbons, or PAHs, that commonly occur in the environment as mixtures such as diesel exhaust and cigarette ...

How cancer tricks the lymphatic system into spreading tumors

2015-05-11
Swollen lymph nodes are often the earliest sign of metastatic spread of cancer cells. Now cancer researchers and immunologists at Sweden's Karolinska Institutet have discovered how cancer cells can infiltrate the lymphatic system by 'disguising' themselves as immune cells (white blood cells). The researchers hope that this finding, which is published in the scientific journal Oncogene, will inform the development of new drugs. The main reason why people die of cancer is that the cancer cells spread to form daughter tumours, or metastases, in vital organs, such as the ...

Nurses cut stress 40 percent with relaxation steps at work

Nurses cut stress 40 percent with relaxation steps at work
2015-05-11
COLUMBUS, Ohio - A study by researchers at The Ohio State University Wexner Medical Center found that a workplace mindfulness-based intervention reduced stress levels of employees exposed to a highly stressful occupational environment. Members of a surgical intensive care unit at the large academic medical center were randomized to a stress-reduction intervention or a control group. The 8-week group mindfulness-based intervention included mindfulness, gentle stretching, yoga, meditation and music conducted in the workplace. Psychological and biological markers of stress ...

Certain treatments for childhood cancer may increase obesity risk later in life

2015-05-11
Individuals who had cancer as a child may be at increased risk of being obese due to the therapies they received during their youth. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest the need for effective counseling and weight loss interventions for certain childhood cancer survivors. Previous research has shown that obesity rates are elevated in childhood cancer survivors who were exposed to cranial radiation, which is used to prevent or delay the spread of cancer ...

First-in-class antibody mixture shows clinical activity against Tx-resistant, advanced CRC

2015-05-11
Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options. Over the last decade, some of the mechanisms driving resistance have been identified, but despite intensive research, treatment options available for patients have not improved, Tabernero said. Sym004 is a 1:1 mixture in the same infusion bag of two antibodies that bind to different regions of the extracellular domain of EGFR, according ...

World first survey uncovers widespread homophobia at UK sports events

2015-05-10
The world's first international study on homophobia in sport, "Out on the Fields," has found widespread homophobia in UK sport, prompting calls for a zero tolerance approach towards discrimination and better training for coaches, teachers and officials. The research, on behalf of the Bingham Cup (the world cup of gay rugby) and affiliated sports groups, was conducted by the global sports market research firm Repucom and overseen by a panel of seven academics from six universities, including Brunel University London. Participants were from the United Kingdom, Ireland, ...

New tool helps researchers, managers plan for sea scallop fishery in the future

2015-05-08
Sea scallops, one of the most valuable commercial fisheries in the United States, are a well managed and monitored fishery, yet little is known about how changing ocean temperatures and ocean chemistry and other environmental factors could impact the fishery. A new study published May 6 in PLOS ONE describes a new computer model to help inform scallop management discussions and decisions in the coming decades. Researchers from the Woods Hole Oceanographic Institution (WHOI), NOAA Fisheries' Northeast Fisheries Science Center (NEFSC), and Ocean Conservancy developed an ...

What would Optimus Prime do? New research taps Transformers to shed light on business leadership

2015-05-08
BINGHAMTON, NY -According to new research co-authored by Binghamton University's Seth Spain, there is more than meets the eye when it comes to the impact of Saturday morning cartoons. The research examines how fantasy-based stories, in particular the popular 1980s cartoon series The Transformers, can shape children's perceptions of what behaviors are associated with effective leadership. It also could provide a basis for workplace-training programs. "We believe that Transformers presents three key lessons about leadership," said Spain, an assistant professor of organizational ...

Thirty-day wait before tubal sterilization is unjust, say ob/gyn experts

2015-05-08
Philadelphia, PA, May 7, 2015 - Current U.S. health policy requires Medicaid beneficiaries to wait 30 days before tubal sterilization. Ob/gyn experts argue that this violates health care justice as elective tubal sterilization is readily available to women with a private source of payment. Writing in the American Journal of Obstetrics & Gynecology, they urge obstetricians to advocate for change to eliminate health care injustice in women's access to elective tubal sterilization. One of the most common forms of contraception in the U.S. is tubal sterilization after childbirth, ...

New study analyzes 'thinspiration' images of women on social media sites

2015-05-08
Some of the most popular social media sites are filled with images of extremely thin women that might be harmful to those who view them -- whether they are seeking them or not, according to research from the University of California, Davis. The images were often cropped to remove heads or focus on just a few body parts. Doctoral candidate Jannath Ghaznavi and associate professor Laramie Taylor in the Department of Communication examined about 300 photographs from Twitter and Pinterest postings that used the terms "thinspiration" and/or "thinspo" to tag images and ideas ...

LAST 30 PRESS RELEASES:

New register opens to crown Champion Trees across the U.S.

A unified approach to health data exchange

New superconductor with hallmark of unconventional superconductivity discovered

Global HIV study finds that cardiovascular risk models underestimate for key populations

New study offers insights into how populations conform or go against the crowd

Development of a high-performance AI device utilizing ion-controlled spin wave interference in magnetic materials

WashU researchers map individual brain dynamics

Technology for oxidizing atmospheric methane won’t help the climate

US Department of Energy announces Early Career Research Program for FY 2025

PECASE winners: 3 UVA engineering professors receive presidential early career awards

‘Turn on the lights’: DAVD display helps navy divers navigate undersea conditions

MSU researcher’s breakthrough model sheds light on solar storms and space weather

Nebraska psychology professor recognized with Presidential Early Career Award

New data shows how ‘rage giving’ boosted immigrant-serving nonprofits during the first Trump Administration

Unique characteristics of a rare liver cancer identified as clinical trial of new treatment begins

From lab to field: CABBI pipeline delivers oil-rich sorghum

Stem cell therapy jumpstarts brain recovery after stroke

Polymer editing can upcycle waste into higher-performance plastics

Research on past hurricanes aims to reduce future risk

UT Health San Antonio, UTSA researchers receive prestigious 2025 Hill Prizes for medicine and technology

Panorama of our nearest galactic neighbor unveils hundreds of millions of stars

A chain reaction: HIV vaccines can lead to antibodies against antibodies

Bacteria in polymers form cables that grow into living gels

Rotavirus protein NSP4 manipulates gastrointestinal disease severity

‘Ding-dong:’ A study finds specific neurons with an immune doorbell

A major advance in biology combines DNA and RNA and could revolutionize cancer treatments

Neutrophil elastase as a predictor of delivery in pregnant women with preterm labor

NIH to lead implementation of National Plan to End Parkinson’s Act

Growth of private equity and hospital consolidation in primary care and price implications

Online advertising of compounded glucagon-like peptide-1 receptor agonists

[Press-News.org] Advanced viral gene therapy eradicates prostate cancer in preclinical experiments
Novel therapy shows synergism between engineered 'cancer terminator virus' and experimental drug to destroy primary and metastatic prostate cancer